Comparative neuroprotective effects of methylprednisolone and rosiglitazone, a peroxisome proliferator-activated receptor-γ following spinal cord injury

Neurosciences

Volumn 16, Issue 1, 2011, Pages 46-52

  Zhang, Qin ^a,b   Huang, Chen ^a   Tang, Tiansi ^a   Shi, Qin ^a   Yang, Huilin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Yuncheng Central Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HEAT SHOCK PROTEIN 70; INTERLEUKIN BETA; METHYLPREDNISOLONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BAX; PROTEIN BCL 2; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; MALE; MOTOR PERFORMANCE; MYELITIS; NERVE CELL NECROSIS; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; RAT; SPINAL CORD INJURY; SPINAL CORD LESION; SPRAGUE DAWLEY RAT; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HSP72 HEAT-SHOCK PROTEINS; IN SITU NICK-END LABELING; INTERLEUKIN-1BETA; MALE; METHYLPREDNISOLONE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD INJURIES; THIAZOLIDINEDIONES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951906558     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 2004; 4: 451-464.
2. McTigue DM. Potential Therapeutic Targets for PPARgamma after Spinal Cord Injury. PPAR Res 2008; 2008: 517162.
3. Jones TB, McDaniel EE, Popovich PG. Inflammatory-mediated injury and repair in the traumatically injured spinal cord. Curr Pharm Des 2005; 11: 1223-1236.
4. Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 2002; 59: 790-798.
5. Satapati S, He T, Inagaki T, Potthoff M, Merritt ME, Esser V, et al. Partial resistance to peroxisome proliferator-activated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism. Diabetes 2008; 57: 2012-2021.
6. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008; 13: 1813-1826.
7. Tolman KG, Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003; 7: 369-379.
8. Kursawe R, Narayan D, Cali AM, Shaw M, Pierpont B, Shulman GI, et al. Downregulation of ADIPOQ and PPARγ2 gene expression in subcutaneous adipose tissue of obese adolescents with hepatic steatosis. Obesity (Silver Spring) 2010; 18: 1911-1917.
9. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123: 993-999.
10. Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005; 191: 331-336.
11. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004; 88: 494-501.
12. Victor NA, Wanderi EW, Gamboa J, Zhao X, Aronowski J, Deininger K, et al. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci 2006; 24: 1653-1663.
13. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 2008; 1244: 164-172.
14. Zhang Q, Hu W, Meng B, Tang T. PPARgamma agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res 2010. [Epub ahead of print]
15. Toumpoulis IK, Anagnostopoulos CE, Drossos GE, Malamou-Mitsi VD, Pappa LS, Katritsis DG. Early ischemic preconditioning without hypotension prevents spinal cord injury caused by descending thoracic aortic occlusion. J Thorac Cardiovasc Surg 2003; 125: 1030-1036.
16. Housley WJ, O'Conor CA, Nichols F, Puddington L, Lingenheld EG, Zhu L, et al. PPARgamma regulates retinoic acid-mediated DC induction of Tregs. J Leukoc Biol 2009; 86: 293-301.
17. Mcdonald JW, Stefovska VG, Liu XZ, Shin H, Liu S, Choi DW. Neurotrophin potentiation of iron-induced spinal cord injury. Neuroscience 2002; 115: 931-939.
18. Wan Y, Evans RM. Rosiglitazone activation of PPARgamma suppresses fractalkine signaling. J Mol Endocrinol 2010; 44: 135-142.
19. Genovese T, Esposito E, Mazzon E, Crisafulli C, Paterniti I, Di Paola R, et al. PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma. Pharmacol Res 2009; 59: 338-350.
20. Rabchevsky AG, Fugaccia I, Sullivan PG, Blades DA, Scheff SW. Efficacy of methylprednisolone therapy for the injured rat spinal cord. J Neurosci Res 2002; 68: 7-18.
21. Plunkett JA, Yu CG, Easton JM, Bethea JR, Yezierski RP. Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. Exp Neurol 2001; 168: 144-154.
22. Chi LY, Yu J, Zhu H, Li XG, Zhu SG, Kindy MS. The dual role of tumor necrosis factor-alpha in the pathophysiology of spinal cord injury. Neurosci Lett 2008; 438: 174-179.
23. Furlan JC, Bracken MB, Fehlings MG. Is age a key determinant of mortality and neurological outcome after acute traumatic spinal cord injury? Neurobiol Aging 2010; 31: 434-446
24. Carrillo-Ruiz JD, Andrade P, Silva F, Vargas G, Maciel-Navarro MM, Jiménez-Botello LC. Olfactory bulb implantation and methylprednisolone administration in the treatment of spinal cord injury in rats. Neurosci Lett 2009; 462: 39-44.
25. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003; 85: 267-2673.
26. Gupta D, Kono T, Evans-Molina C. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab 2010; 12: 1036-1047.
27. Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R. PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol 2010; 23: 343-352.
28. Yi JH, Park SW, Kapadia R, Vemuganti R. Role of transcription factors in mediating post-ischemic cerebral inflammation and brain damage. Neurochem Int 2007; 50: 1014-1027.
29. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005; 13: 950-958.
30. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptorgamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005; 130: 685-696.
31. Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, et al. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 2005; 36: 353-359.
32. Tureyen K, Kapadia R, Bowen KK, Satriotomo I, Liang J, Feinstein DL, et al. Peroxisome proliferator-activated receptorgamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007; 101: 41-56.
33. Zhao X, Zhang Y, Strong R, Grotta JC, Aronowski J. 15d- Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 2006; 26: 811-820.
34. Genovese T, Esposito E, Mazzon E, Di Paola R, Muià C, Meli R, Bramanti P, Cuzzocrea S. Effect of cyclopentanone prostaglandin 15-deoxy-delta12,14PGJ2 on early functional recovery from experimental spinal cord injury. Shock 2008; 30: 142-152.
35. Alexander JK, Popovich PG. Neuroinflammation in spinal cord injury: therapeutic targets for neuroprotection and regeneration. Prog Brain Res 2009; 175: 125-137
36. Ankeny DP, Popovich PG. Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience 2009; 158: 1112-1121
37. Song G, Cechvala C, Resnick DK, Dempsey RJ, Rao VL. GeneChip analysis after acute spinal cord injury in rat. J Neurochem 2001; 79: 804-815.
38. Tachibana T, Noguchi K, Ruda MA. Analysis of gene expression following spinal cord injury in rat using complementary DNA microarray. Neurosci Lett 2002; 327: 133-137.
39. Bale TL, Picetti R, Contarino A, Koob GF, Vale WW, Lee KF. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci 2002; 22: 193-199.
40. Kawai M, Green CB, Lecka-Czernik B, Douris N, Gilbert MR, Kojima S, et al. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. Proc Natl Acad Sci U S A 2010; 107: 10508-10513.